Altamira Therapeutics Ltd Stock Price, News & Analysis

Altamira Therapeutics (NASDAQ:CYTO) announced reaching its target enrollment of 136 subjects in the COVAMID clinical trial, evaluating the safety and efficacy of its Bentrio nasal spray for treating acute COVID-19. The company anticipates top-line data by Q3-22, following an interim analysis to confirm statistical assumptions. Depending on the analysis, enrollment may extend to 180 patients. A positive trial outcome could lead to label expansion for Bentrio in countries requiring supportive clinical data. Bentrio is designed to protect against airborne viruses and allergens.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced encouraging results from its Phase 2 TRAVERS trial of AM-125, an intranasal formulation of betahistine for treating acute vertigo. The trial, involving 124 patients, showed a significant improvement in balance after four weeks of treatment, with participants maintaining balance for an average of 12.5 seconds compared to 7.5 seconds for the placebo group (p=0.0242). AM-125 was well-tolerated, with 34.5% of the treatment group experiencing resolution of nystagmus. The company plans to file a US FDA IND application and is looking to advance the development of AM-125.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) received a notification from the Nasdaq Listings Qualifications Department on June 2, 2022, indicating that its share price had fallen below the $1.00 minimum requirement for 30 consecutive business days. The company has a 180-day compliance period to regain compliance, during which a closing bid price of at least $1.00 for 10 consecutive days will confirm compliance. If necessary, an additional 180 days may be granted under specific conditions, including a potential reverse stock split.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced positive results from tests on Bentrio™, a drug-free nasal spray, demonstrating significant protective effects against human rhinovirus (HRV). The study showed an 89.5% reduction in viral load after preventive treatment and 98.9% after mitigative treatment compared to saline controls on Day 4. Bentrio is designed to form a protective gel in the nasal mucosa, reducing infection risk and alleviating allergic symptoms. The company anticipates further distribution in Europe and pending FDA approval for allergic rhinitis treatment.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its product Bentrio has received approval from Indonesia's Ministry of Health for commercialization. Bentrio is a drug-free nasal spray aimed at providing protection against airborne allergens and viruses. The product will be marketed through Wellesta Holdings Pte Ltd, covering a broad Territory including India and Southeast Asia. This approval adds to Bentrio's existing clearances in Singapore, Malaysia, and the Philippines, expanding its market reach in a country with approximately 277 million people.

Altamira Therapeutics Ltd. (NASDAQ: CYTO) announced that the Philippines' FDA has approved Bentrio, its nasal spray, for commercialization in the country. Bentrio offers protection against airborne allergens and viruses and will be distributed by Wellesta Holdings across various Asian countries. Positive data from recent clinical trials indicate Bentrio's efficacy against house dust mites, a common cause of allergies. This expansion into the Philippines presents a significant market opportunity, targeting a population of 115 million.

Altamira Therapeutics (NASDAQ:CYTO) announced positive results from its clinical trial of Bentrio nasal spray for house dust mite (HDM) allergic rhinitis. The study, involving 37 patients, showed a statistically significant reduction in nasal symptoms compared to untreated controls, with a decrease in the Total Nasal Symptom Score (TNSS) by 1.1 points (p<0.01). Bentrio, a drug-free product, demonstrated good tolerability, with over 85% of participants rating it positively. The company aims to continue the commercial roll-out of Bentrio as an effective over-the-counter treatment.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Thomas Meyer will discuss the company's transition to RNA therapeutics and its ongoing projects, including the Bentrio nasal spray, which recently gained regulatory approval in North Macedonia for use in COVID-19 trials. The presentation is scheduled for May 24, 2022, at 7:00 AM ET. Altamira focuses on therapies for unmet medical needs in areas like RNA therapeutics and treatments for hearing loss.

Altamira Therapeutics (NASDAQ: CYTO) outlined its recent progress and future outlook in a shareholder letter dated May 18, 2022. The company is transitioning to a pure-play RNA therapeutics business targeting a $50 billion total addressable market (TAM). Key highlights include advancements in their RNA AM-401 program for KRAS-driven cancers, ongoing clinical trials for their nasal spray Bentrio, and upcoming data from the AM-125 nasal spray for vertigo. The plan includes divesting non-RNA legacy assets by year-end 2022 to fully focus on RNA developments.